Keywords: Prostate, PET/MR
For patients with suspected prostate cancer recurrence, we examined the added value of 18F-PSMA-1007 PET to MR and CT imaging, and whether choice of PET modality, i.e. PET/MR or PET/CT, had an impact on clinical management. An intention-to-treat analysis was performed using findings from MR and CT alone, MR and CT with PET from PET/CT, and MR and CT with PET from PET/MR. Addition of 18F-PSMA PET changed clinical management in over 40% of patients. Differences in clinical management between PET/CT and PET/MR were smaller than adding any PET modality to MR and CT.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords